South Korea Will Not Pursue Compulsory Licensing Against MNCs, But For How Long?
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The South Korean government currently has no plans to implement compulsory licensing to help rein in costs for Korean patients being treated for fatal diseases, but will reconsider its stance should negotiations with industry break down, Jeon Jae-Hee, the Minister for Health, Welfare and Family Affairs said Feb. 23
You may also be interested in...
Korea's Ilyang Pharmaceutical Starts Phase III Trials For First-line CML Drug To Compete With Gleevec
SEOUL - South Korea's Ilyang Pharmaceutical Co. Ltd. recently started Phase III trials for novel leukemia drug Supect (rodotinib) in Korea, India, Thailand, Philippines and Indonesia to determine whether it can gain approval in Korea as a first-line treatment for chronic myeloid leukemia and take on Novartis AG's Gleevec (imatinib). The company aspires to then bring the product to other Asian markets, and then eventually the U.S
Korea's Ilyang Pharmaceutical Starts Phase III Trials For First-line CML Drug To Compete With Gleevec
SEOUL - South Korea's Ilyang Pharmaceutical Co. Ltd. recently started Phase III trials for novel leukemia drug Supect (rodotinib) in Korea, India, Thailand, Philippines and Indonesia to determine whether it can gain approval in Korea as a first-line treatment for chronic myeloid leukemia and take on Novartis AG's Gleevec (imatinib). The company aspires to then bring the product to other Asian markets, and then eventually the U.S
Korea Reveals More On Plans To Grow Bioclusters At Osong And Daegu
SEOUL - The Korean government announced more details on how it plans to cultivate its multibillion dollar, high-tech pharmaceutical R&D projects in Osong and Daegu